SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Politics : Politics for Pros- moderated -- Ignore unavailable to you. Want to Upgrade?

To: frankw1900 who wrote (722666)7/31/2020 9:04:46 PM
From: skinowski1 Recommendation

Recommended By
Maurice Winn

  Read Replies (2) | Respond to of 794009
 
Hey Frank, I think that large beautiful bridge you have for sale isn’t over Hudson, it’s over the East River. Other than that, we’re in agreement :)

Of course, they would say they don’t believe that the medication works - so, until proven, there isn’t an ethical dilemma. I think one solution would be to refrain from taking the double blind path, using placebo - and simply use as controls those patients who refuse HCQ. With enough numbers, the results would be plenty significant.

You’re right - at this point, I wouldn’t be comfortable giving placebo to people who would have chosen HCQ.

It’s true - double blind randomized placebo controlled trials are the gold standard - but it’s not the only standard.



To: frankw1900 who wrote (722666)8/1/2020 11:53:11 AM
From: skinowski2 Recommendations

Recommended By
alanrs
Thomas M.

  Read Replies (2) | Respond to of 794009
 
So, Dr Fauci wants a double blind, properly randomized study in order to become a believer in HCQ? So why did he cancel the one that was started by the institution he happens to be running???



HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News